Intended for healthcare professionals


TADS study raises concerns

BMJ 2004; 329 doi: (Published 02 December 2004) Cite this as: BMJ 2004;329:1343
  1. Jon Jureidini (, head,
  2. Anne Tonkin, associate professor, department of clinical and experimental pharmacology,
  3. Peter R Mansfield, research fellow, department of general practice
  1. Department of Psychological Medicine, Women's and Children's Hospital, North Adelaide 5006, Australia
  2. University of Adelaide, Adelaide 5005, Australia

    EDITOR—We have additional concerns to those raised by Lenzer about the adolescents with depression study (TADS).1 2

    TADS consists of two separate randomised studies: a double blind comparison of fluoxetine (109 subjects) with placebo (112), and an unblinded comparison between cognitive behaviour therapy alone (111) and fluoxetine plus cognitive behaviour therapy (107). The lack of patient blinding and placebo control in the latter group is likely to exaggerate the benefit seen in the fluoxetine plus cognitive behaviour therapy group, who receive more face to …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription